Pharmaids - 2026 Company Profile, Team & Financials

About Pharmaids

Pharmaids is a publicly listed company based in Hyderabad (India) founded in 1989. Pharmaids is recognized as a provider of custom research and manufacturing services for pharmaceutical and related industries. It operates on a Professional Services and B2B2C model. The company has 28 employees. Its Indian entity Pharmaids Pharmaceuticals Limited reported revenue of ₹30.92 Cr. Pharmaids offers products and services including R&D Services, Manufacturing Services, Pharma Intermediates, and Active Pharmaceutical Ingredients. Its focus areas include Pharmaceuticals and Custom Research and Manufacturing.

Company details

Pharmaids Pharmaceuticals Limited is established as a fully integrated provider of Custom Research and Manufacturing Services (CRAMS). Solutions are delivered to industries including pharmaceuticals, biotechnology, agrochemicals, and chemicals. Comprehensive services are offered, encompassing research and development in chemistry and biology, manufacturing of new chemical entities (NCEs), key intermediates, and active pharmaceutical ingredients (APIs). State-of-the-art facilities are utilized to support process chemistry and kilo-scale manufacturing. A range of quality and cost-effective pharma intermediates is provided, alongside the development of niche APIs for pharmaceutical, nutraceutical, and veterinary applications. Operations are conducted with a focus on innovation and tailored solutions to meet industry needs.

Headquarters Hyderabad, India
Employees 28
Stage Public
Sectors
Healthcare
Email
••••••••
Phone
•••• ••••
Website pharmaids.com
Social X
Legal Name Pharmaids Pharmaceuticals Ltd.

Operational Areas

Healthcare → Traditional Health & Nutrition

Key Metrics

Market Cap
₹99.77 Cr
PHARMAID · BSE
Share Price
₹29.00
+2.51% today
Revenue
₹27.88 Cr
FY 2025-26 · +43.3% YoY
EBITDA
−₹13.80 Cr
Margin -49.5%
Net Profit
−₹14.19 Cr
FY 2025-26 · -33.0% YoY
Debt / Equity
0.58
Interest cover -22.2x
Employee Count
28

Associated legal entities of Pharmaids

Pharmaids operates through Pharmaids Pharmaceuticals Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.

Legal entity	Status	Incorporated	Registered in	Revenue (FY 2026)	Employees	Directors	Company page
Pharmaids Pharmaceuticals Limited Listed CIN L52520KA1989PLC173979	Active	01 Mar 1989	Bangalore, Karnataka	₹30.9 Cr	21	9	View details

Products & Services of Pharmaids

Pharmaids offers a comprehensive portfolio of products and services, including R&D Services, Manufacturing Services, Pharma Intermediates, and Active Pharmaceutical Ingredients.

R&D Services

Research and Development

Research services are provided for chemistry and biology.

Manufacturing Services

CDMO Services

Manufacturing of NCEs and APIs is facilitated here.

Pharma Intermediates

Pharmaceuticals

Quality pharma intermediates are developed and supplied efficiently.

Active Pharmaceutical Ingredients

Pharmaceuticals

Niche APIs are developed for various applications.

Board of directors of Pharmaids Pharmaceuticals Limited (Pharmaids)

Pharmaids Pharmaceuticals Limited is the primary company behind Pharmaids. The board of Pharmaids Pharmaceuticals Limited currently have 9 directors; the longest-serving is Venu Madhava Kaparthy, appointed in 2022. 21 earlier directors have ceased.

Director	Designation	Appointed	Tenure	Entity
Venu Madhava Kaparthy DIN 00021699	Whole-time director	21 May 2022	4 yrs 5 mo	Pharmaids Pharmaceuticals Limited
Mini Manikantan DIN 09663184	Whole-time director	09 Jul 2022	4 yrs 3 mo	Pharmaids Pharmaceuticals Limited
Balagangadhara Bidanagere Channathimmaiah DIN 09658079	CFO	13 Oct 2022	4 yrs	Pharmaids Pharmaceuticals Limited
Pattamadai Natarajasarma Vijay DIN 00049992	Director	31 Oct 2022	3 yrs 11 mo	Pharmaids Pharmaceuticals Limited
Nagesh Methuku DIN 01634324	Director	29 Nov 2022	3 yrs 10 mo	Pharmaids Pharmaceuticals Limited
Shreedhara Shetty DIN 02776638	Director	29 Aug 2023	3 yrs 1 mo	Pharmaids Pharmaceuticals Limited
Shankarappa Nagaraja Vinaya Babu DIN 01373832	Director	31 Jan 2024	2 yrs 8 mo	Pharmaids Pharmaceuticals Limited
Prasanna Subramanya Bhat DIN 08565364	Company Secretary	26 Aug 2024	2 yrs 1 mo	Pharmaids Pharmaceuticals Limited
Yogananda Moolemath DIN 02870387	Director	01 Jan 2026	9 mo	Pharmaids Pharmaceuticals Limited

IPO & Listings of Pharmaids

Pharmaids is a publicly listed company on the BSE with ticker symbol PHARMAID in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

IPO date04 Sep 2001
Listed onBSE: 524572
Listed entityPharmaids Pharmaceuticals Ltd.
Exchange sectorHealth technology
ISININE117D01018
Share price₹30.10 (+0.4% on the day) · 2026-10-14
Market capitalisation₹106 Cr
EPS (diluted, trailing year)₹-1.29
Volume (last session)3,601

Financials of Pharmaids

Exchange-reported figures of Pharmaids Pharmaceuticals Limited, the listed company behind Pharmaids (BSE: PHARMAID).

Financial Highlights

FY 2025-26 · Consolidated

Revenue

₹27.88 Cr

+43.3% YoY

EBITDA

−₹13.80 Cr

-7.1% YoY

Profit After Tax

−₹14.19 Cr

-33.0% YoY

Net Worth

₹47.66 Cr

-19.7% YoY

Total Assets

₹72.96 Cr

-24.8% YoY

Total Debt

₹23.39 Cr

-40.0% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

Metrics	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22
Income statement
Revenue	27.88	19.45	15.11	0.00	3.94
Revenue growth	+43.3%	+28.7%	-	-100.0%	-
EBITDA	(13.80)	(12.89)	(13.20)	(9.89)	0.14
EBITDA margin	-49.5%	-66.3%	-87.4%	-	+3.6%
Profit before tax	(16.31)	(17.28)	(15.62)	(9.91)	0.15
Net profit	(14.19)	(10.67)	(7.11)	(7.56)	0.15
Net profit margin	-50.9%	-54.9%	-47.1%	-	+3.8%
EPS (₹)	(3.32)	(3.06)	(2.26)	(3.52)	0.14
Balance sheet
Total assets	72.96	96.99	82.24	22.46	8.67
Net worth	47.66	59.32	72.05	22.46	8.67
Total debt	23.39	38.98	8.53	0.00	0.00
Cash & bank	0.13	0.82	4.80	12.75	0.41
Net working capital	(3.32)	(1.88)	4.43	12.08	0.23
Cash flow
Cash from operations	(4.06)	(15.11)	(10.62)	(4.02)	(0.26)
Cash from investing	23.34	(12.22)	(74.99)	(4.94)	0.47
Cash from financing	(19.97)	23.36	77.66	21.31	0.00

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	4.12	7.18	5.43	8.61	6.66	4.77	4.71	5.24
Revenue growth (YoY)	-38.1%	+50.5%	+15.3%	+64.3%	+40.8%	-	-	-
Other income	4.25	0.10	0.08	3.03	0.04	0.13	0.01	0.08
EBITDA	(0.75)	(0.43)	(2.90)	(5.32)	(5.38)	(3.91)	(2.90)	(2.41)
EBITDA margin	-18.2%	-6.0%	-53.4%	-61.8%	-80.8%	-82.0%	-61.6%	-46.0%
Depreciation	0.49	0.48	0.48	0.47	0.61	0.62	0.64	0.61
Interest	0.60	0.65	0.72	0.93	1.20	1.01	0.48	0.33
Profit before tax	2.41	(1.46)	(4.02)	(3.69)	(7.15)	(5.41)	(4.01)	(3.27)
Tax	0.54	(0.37)	(1.38)	(1.13)	(1.86)	(0.60)	(1.00)	(1.00)
Net profit	1.87	(1.09)	(2.64)	(2.56)	(5.29)	(4.81)	(3.01)	(2.27)
EPS (₹)	0.63	(0.51)	(0.70)	(0.70)	(1.39)	(1.11)	(0.55)	(0.73)

Metrics	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Income statement
Revenue	10.60	2.34	0.03	0.00	3.94	8.55	0.00
Revenue growth	+353.0%	+7700.0%	-	-100.0%	-53.9%	-	-
EBITDA	(14.26)	(7.26)	(6.36)	(9.90)	0.14	0.11	(0.33)
EBITDA margin	-134.5%	-310.3%	-	-	+3.6%	+1.3%	-
Profit before tax	(13.97)	(8.59)	(6.07)	(9.92)	0.15	0.10	(0.37)
Net profit	(13.56)	(7.28)	(4.93)	(7.57)	0.15	0.10	0.04
Net profit margin	-127.9%	-311.1%	-	-	+3.8%	+1.2%	-
EPS (₹)	(2.96)	(2.06)	(1.40)	(3.52)	0.14	0.09	0.03
Balance sheet
Total assets	74.02	99.64	84.04	22.43	8.67	8.53	8.43
Net worth	53.38	63.79	71.06	22.42	8.67	8.53	8.43
Total debt	20.63	35.74	12.93	0.00	0.00	0.00	0.00
Cash & bank	0.11	0.47	2.46	12.75	0.41	0.20	0.02
Net working capital	(4.12)	(2.39)	3.81	12.87	0.23	0.27	0.35
Cash flow
Cash from operations	(3.53)	(7.72)	(3.44)	(4.02)	(0.26)	0.41	(0.75)
Cash from investing	24.53	(18.90)	(72.51)	(4.95)	0.47	(0.23)	0.66
Cash from financing	(21.36)	24.64	65.66	21.31	0.00	0.00	0.00

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	0.00	2.69	0.83	5.97	1.12	0.13	1.21	0.83
Revenue growth (YoY)	-100.0%	+1969.2%	-31.4%	+619.3%	+558.8%	-	-	-
Other income	4.25	0.06	0.06	3.32	0.35	1.01	0.00	0.01
Total expenses	0.87	3.79	4.51	10.54	5.99	2.81	2.94	1.96
EBITDA	(0.87)	(1.10)	(3.68)	(4.57)	(4.87)	(2.68)	(1.73)	(1.13)
EBITDA margin	-	-40.9%	-443.4%	-76.5%	-434.8%	-2061.5%	-143.0%	-136.1%
Depreciation	0.06	0.05	0.05	0.06	0.05	0.05	0.05	0.05
Interest	0.57	0.60	0.57	1.02	1.11	2.05	0.07	0.01
Profit before tax	2.75	(1.69)	(4.24)	(2.33)	(5.68)	(3.77)	(1.85)	(1.18)
Tax	0.61	(0.38)	(1.13)	(0.68)	(1.33)	(0.72)	(0.25)	(0.18)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	4.12	7.18	5.43	8.61	6.66	4.77	4.71	5.24
Revenue growth (YoY)	-38.1%	+50.5%	+15.3%	+64.3%	+40.8%	-	-	-
Other income	4.25	0.10	0.08	3.03	0.04	0.13	0.01	0.08
EBITDA	(0.75)	(0.43)	(2.90)	(5.32)	(5.38)	(3.91)	(2.90)	(2.41)
EBITDA margin	-18.2%	-6.0%	-53.4%	-61.8%	-80.8%	-82.0%	-61.6%	-46.0%
Depreciation	0.49	0.48	0.48	0.47	0.61	0.62	0.64	0.61
Interest	0.60	0.65	0.72	0.93	1.20	1.01	0.48	0.33
Profit before tax	2.41	(1.46)	(4.02)	(3.69)	(7.15)	(5.41)	(4.01)	(3.27)
Tax	0.54	(0.37)	(1.38)	(1.13)	(1.86)	(0.60)	(1.00)	(1.00)
Net profit	1.87	(1.09)	(2.64)	(2.56)	(5.29)	(4.81)	(3.01)	(2.27)
EPS (₹)	0.63	(0.51)	(0.70)	(0.70)	(1.39)	(1.11)	(0.55)	(0.73)

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22
Revenue	27.88	19.45	15.11	0.00	3.94
Revenue growth	+43.3%	+28.7%	-	-100.0%	-
Other income	3.04	0.15	0.88	0.00	0.02
Total expenses	41.68	32.34	28.31	9.89	3.80
Employee cost	13.38	13.16	9.20	1.13	0.04
EBITDA	(13.80)	(12.89)	(13.20)	(9.89)	0.14
EBITDA margin	-49.5%	-66.3%	-87.4%	-	+3.6%
Depreciation	2.03	2.44	1.72	0.02	0.01
Interest	3.52	2.10	1.58	0.00	0.00
Profit before tax	(16.31)	(17.28)	(15.62)	(9.91)	0.15
Tax	(4.73)	(3.78)	(3.78)	(2.35)	0.00
Net profit	(14.19)	(10.67)	(7.11)	(7.56)	0.15
Net profit margin	-50.9%	-54.9%	-47.1%	-	+3.8%
EPS (₹)	(3.32)	(3.06)	(2.26)	(3.52)	0.14

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22
Equity & liabilities
Share capital	35.27	35.27	35.27	21.44	10.27
Reserves & surplus	12.39	24.05	36.78	0.67	(1.60)
Shareholders' funds (net worth)	47.66	59.32	72.05	22.46	8.67
Minority interest	(0.05)	(4.28)	(1.55)	0.00	0.00
Secured loans	4.98	3.34	0.61	0.00	0.00
Unsecured loans	18.41	35.64	7.92	0.00	0.00
Total debt	23.39	38.98	8.53	0.00	0.00
Total liabilities	72.96	96.99	82.24	22.46	8.67
Assets
Gross block	58.96	81.24	65.20	0.12	0.51
Net block	53.94	76.61	63.42	0.10	0.03
Capital work in progress	6.10	4.53	7.00	2.00	0.45
Investments	0.00	0.00	0.00	3.31	0.00
Inventories	0.41	12.18	3.59	0.00	0.89
Sundry debtors	3.43	3.13	2.68	1.39	1.34
Cash & bank balances	0.13	0.82	4.80	12.75	0.41
Loans & advances	7.01	4.85	2.46	0.07	0.03
Total current assets	10.98	20.98	13.53	14.21	2.67
Total current liabilities	14.30	22.86	9.10	2.13	2.44
Net working capital	(3.32)	(1.88)	4.43	12.08	0.23
Total assets	72.96	96.99	82.24	22.46	8.67

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22
Opening cash	0.82	4.80	12.75	0.41	0.20
Net cash from operating activities	(4.06)	(15.11)	(10.62)	(4.02)	(0.26)
Net cash from investing activities	23.34	(12.22)	(74.99)	(4.94)	0.47
Net cash from financing activities	(19.97)	23.36	77.66	21.31	0.00
Net change in cash	(0.69)	(3.98)	(7.95)	12.35	0.21
Closing cash	0.13	0.82	4.80	12.75	0.41

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22
Growth
Sales growth	+43.3%	+28.7%	-	-100.0%	-
EBITDA growth	-7.1%	+2.4%	-33.5%	-7164.3%	-
PBT growth	+5.6%	-10.6%	-57.6%	-	+9997.0%
Net income growth	-33.0%	-50.1%	+6.0%	-5140.0%	-
Revenue CAGR (3Y)	-	+70.3%	-	-	-
EBITDA CAGR (3Y)	+11.7%	-	-	-	-
Profitability & leverage
Net income margin	-41.5%	-69.4%	-78.4%	-	+3.8%
Return on capital employed	0.0%	0.0%	0.0%	0.0%	+1.4%
Return on net worth	0.0%	0.0%	0.0%	0.0%	+1.4%
Debt / equity	0.58	0.36	0.09	0.00	0.00
Long-term debt / equity	0.44	0.30	0.06	0.00	0.00
Interest cover	-22.24	-13.70	-10.59	0.00	0.00
Efficiency & per share
Fixed asset turnover	0.40	0.27	0.46	0.00	7.73
Inventory turnover	4.43	2.47	8.42	0.00	4.43
Debtors turnover	8.50	6.70	7.43	0.00	2.94
EPS (₹)	(3.32)	(3.06)	(2.26)	(3.52)	0.14
Dividend per share (₹)	0.00	0.00	0.00	0.00	0.00
Book value per share (₹)	13.51	16.82	20.43	10.31	8.44

Particulars	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Revenue	0.00	2.69	0.83	5.97	1.12	0.13	1.21	0.83
Revenue growth (YoY)	-100.0%	+1969.2%	-31.4%	+619.3%	+558.8%	-	-	-
Other income	4.25	0.06	0.06	3.32	0.35	1.01	0.00	0.01
Total expenses	0.87	3.79	4.51	10.54	5.99	2.81	2.94	1.96
EBITDA	(0.87)	(1.10)	(3.68)	(4.57)	(4.87)	(2.68)	(1.73)	(1.13)
EBITDA margin	-	-40.9%	-443.4%	-76.5%	-434.8%	-2061.5%	-143.0%	-136.1%
Depreciation	0.06	0.05	0.05	0.06	0.05	0.05	0.05	0.05
Interest	0.57	0.60	0.57	1.02	1.11	2.05	0.07	0.01
Profit before tax	2.75	(1.69)	(4.24)	(2.33)	(5.68)	(3.77)	(1.85)	(1.18)
Tax	0.61	(0.38)	(1.13)	(0.68)	(1.33)	(0.72)	(0.25)	(0.18)

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Revenue	10.60	2.34	0.03	0.00	3.94	8.55	0.00
Revenue growth	+353.0%	+7700.0%	-	-100.0%	-53.9%	-	-
Other income	3.81	1.02	0.80	0.00	0.02	0.03	0.00
Total expenses	24.86	9.60	6.39	9.90	3.80	8.44	0.33
Employee cost	5.40	3.42	1.99	1.13	0.04	0.04	0.02
EBITDA	(14.26)	(7.26)	(6.36)	(9.90)	0.14	0.11	(0.33)
EBITDA margin	-134.5%	-310.3%	-	-	+3.6%	+1.3%	-
Depreciation	0.21	0.20	0.18	0.02	0.01	0.04	0.04
Interest	3.31	2.15	0.33	0.00	0.00	0.00	0.00
Profit before tax	(13.97)	(8.59)	(6.07)	(9.92)	0.15	0.10	(0.37)
Tax	(3.52)	(1.31)	(1.14)	(2.35)	0.00	0.00	(0.41)
Net profit	(13.56)	(7.28)	(4.93)	(7.57)	0.15	0.10	0.04
Net profit margin	-127.9%	-311.1%	-	-	+3.8%	+1.2%	-
EPS (₹)	(2.96)	(2.06)	(1.40)	(3.52)	0.14	0.09	0.03

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Equity & liabilities
Share capital	35.27	35.27	35.27	21.44	10.27	10.27	10.27
Reserves & surplus	18.11	28.52	35.79	0.98	(1.60)	(1.74)	(1.84)
Shareholders' funds (net worth)	53.38	63.79	71.06	22.42	8.67	8.53	8.43
Secured loans	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Unsecured loans	20.63	35.74	12.93	0.00	0.00	0.00	0.00
Total debt	20.63	35.74	12.93	0.00	0.00	0.00	0.00
Total liabilities	74.02	99.64	84.04	22.43	8.67	8.53	8.43
Assets
Gross block	8.64	24.57	16.75	0.12	0.51	0.51	0.51
Net block	8.05	24.18	16.56	0.10	0.03	0.04	0.09
Capital work in progress	5.47	3.51	2.30	2.00	0.45	0.45	0.45
Investments	52.54	52.61	52.60	3.27	0.00	0.00	0.00
Inventories	0.00	9.77	0.23	0.00	0.89	0.37	0.00
Sundry debtors	1.38	0.16	0.00	2.05	1.34	0.28	0.00
Cash & bank balances	0.11	0.47	2.46	12.75	0.41	0.20	0.02
Loans & advances	4.33	2.29	2.07	0.20	0.03	0.01	0.36
Total current assets	5.82	12.69	4.76	15.00	2.67	0.86	0.38
Total current liabilities	9.94	15.08	0.95	2.13	2.44	0.59	0.03
Net working capital	(4.12)	(2.39)	3.81	12.87	0.23	0.27	0.35
Total assets	74.02	99.64	84.04	22.43	8.67	8.53	8.43

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Opening cash	0.47	2.46	12.75	0.41	0.20	0.02	0.11
Net cash from operating activities	(3.53)	(7.72)	(3.44)	(4.02)	(0.26)	0.41	(0.75)
Net cash from investing activities	24.53	(18.90)	(72.51)	(4.95)	0.47	(0.23)	0.66
Net cash from financing activities	(21.36)	24.64	65.66	21.31	0.00	0.00	0.00
Net change in cash	(0.36)	(1.99)	(10.29)	12.35	0.21	0.18	(0.09)
Closing cash	0.11	0.47	2.46	12.75	0.41	0.20	0.02

Particulars	FY 2025-26	FY 2024-25	FY 2023-24	FY 2022-23	FY 2021-22	FY 2020-21	FY 2019-20
Growth
Sales growth	+353.0%	+7700.0%	-	-100.0%	-53.9%	-	-
EBITDA growth	-96.4%	-14.2%	+35.8%	-7171.4%	+27.3%	+133.3%	-
PBT growth	-62.6%	-41.5%	+38.8%	-	+50.0%	+9998.0%	-146.7%
Net income growth	-86.3%	-47.7%	+34.9%	-5146.7%	+50.0%	+150.0%	-
Revenue CAGR (3Y)	-	-15.9%	-84.8%	-	+91.6%	+166.8%	-100.0%
EBITDA CAGR (3Y)	+12.9%	-	-	+210.7%	-	-	-1.9%
Profitability & leverage
Net income margin	-98.6%	-311.1%	-	-	+3.8%	+1.2%	-
Return on capital employed	0.0%	0.0%	0.0%	0.0%	+1.4%	+0.8%	-3.9%
Return on net worth	0.0%	0.0%	0.0%	0.0%	+1.4%	+0.8%	+0.3%
Debt / equity	0.48	0.36	0.14	0.00	0.00	0.00	0.00
Long-term debt / equity	0.43	0.36	0.14	0.00	0.00	0.00	0.00
Interest cover	-22.87	-28.82	-5.05	0.00	0.00	0.00	0.00
Efficiency & per share
Fixed asset turnover	0.64	0.11	0.00	0.00	7.73	16.76	0.00
Inventory turnover	2.17	0.47	0.26	0.00	6.25	46.22	0.00
Debtors turnover	13.77	29.25	0.03	0.00	4.86	61.07	0.00
EPS (₹)	(2.96)	(2.06)	(1.40)	(3.52)	0.14	0.09	0.03
Dividend per share (₹)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Book value per share (₹)	15.14	18.09	20.15	10.46	8.44	8.30	8.21

Web traffic of Pharmaids

The website of Pharmaids (pharmaids.com) receives about 9.9K visits a month.

Monthly visits
9.9K
▲ 24.3% vs previous month

Top companies in Traditional Health & Nutrition

3 companies that operate in the same segment as Pharmaids (Traditional Health & Nutrition) in India, ranked by their profile score on The Company Check.

Company	Description	Founded	Location	Total funding	Revenue	Employees
Inventia Healthcare	Oral solid drug delivery systems are manufactured and developed.	1985	Mumbai, Maharashtra, India	USD 42.49 M	USD 89.42 M	962
Strides Pharma Science	Generic, semi-solid, and liquid dosage forms are manufactured.	1990	Bengaluru, Karnataka, India		USD 508.93 M	5,180
Sun Pharma	Specialty generic pharmaceuticals and APIs are manufactured and marketed.	1983	Mumbai, Maharashtra, India		USD 6.21 B	25,870

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.

Included in your Premium account

✓
Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
✓
Full access to every database India & global coverage, advanced filters and rich profile details
✓
Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Pharmaids

Pharmaids Pharmaceuticals reports consolidated net profit of Rs 2.21 crore in the June 2026 quarter | Capital Market News - Business Standard

Business Standard • 2 months ago

PHARMAID: Q1 FY27 saw a return to profit on exceptional income, despite sharply lower revenue

Quartr • 2 months ago

PHARMAID: Revenue up, losses widened; major disinvestments and CRDMO expansion ongoing

Quartr • 4 months ago

PHARMAID: Revenue increased but net losses persisted; borrowings and cash reserves declined

Quartr • 4 months ago

PHARMAID: Quarterly consolidated net loss of Rs. 264.60 lakhs on revenue of Rs. 543 lakhs; lease discontinued

Quartr • 8 months ago

Pharmaids Pharmaceuticals Appoints P N Vijay As Chairman Effective December 05, 2025

Reuters • 10 months ago

PHARMAID: Losses narrowed on higher revenue, with major disinvestment and debt repayment completed

Quartr • 11 months ago

PHARMAID: Q1 FY26 saw higher losses and a pending major divestment, with no impact on current results

Quartr • 1 year ago

Pharmaids Pharmaceuticals reports standalone net loss of Rs 4.36 crore in the June 2025 quarter | Capital Market News - Business Standard

Business Standard • 1 year ago

Pharmaids Pharmaceuticals reports consolidated net loss of Rs 4.95 crore in the June 2025 quarter | Capital Market News - Business Standard

Business Standard • 1 year ago

Premium access

Complete news archive for Pharmaids

Full article history, source details, and older brand coverage require an active premium plan.

Full article archive
Source and publication date
Older coverage
Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Pharmaids

When was Pharmaids founded?

Pharmaids was founded in 1989.

Where is Pharmaids located?

Pharmaids is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

How many employees does Pharmaids have?

Pharmaids has 28 employees.

What is the annual revenue of Pharmaids?

The primary company behind Pharmaids, Pharmaids Pharmaceuticals Limited, reported revenue of ₹30.92 Cr for FY 2026, up 43% year on year.

What does Pharmaids do?

Pharmaids Pharmaceuticals Limited is established as a fully integrated provider of Custom Research and Manufacturing Services (CRAMS). Solutions are delivered to industries including pharmaceuticals, biotechnology, agrochemicals, and chemicals. Comprehensive services are offered, encompassing research and development in chemistry and biology, manufacturing of new chemical entities (NCEs), key intermediates, and active pharmaceutical ingredients (APIs). State-of-the-art facilities are utilized to support process chemistry and kilo-scale manufacturing. A range of quality and cost-effective pharma intermediates is provided, alongside the development of niche APIs for pharmaceutical, nutraceutical, and veterinary applications. Operations are conducted with a focus on innovation and tailored solutions to meet industry needs.

What products or services does Pharmaids offer?

Pharmaids offers R&D Services, Manufacturing Services, Pharma Intermediates, and Active Pharmaceutical Ingredients.

Is Pharmaids publicly traded?

Yes, Pharmaids is publicly traded on BSE under the ticker symbol PHARMAID.

Which legal entities are associated with Pharmaids?

Pharmaids operates through Pharmaids Pharmaceuticals Limited.

Who are the directors of Pharmaids?

The legal entities of Pharmaids currently have 9 directors, including Pattamadai Natarajasarma Vijay, Balagangadhara Bidanagere Channathimmaiah, Venu Madhava Kaparthy and others.